QUEBEC CITY, QUEBEC – November 9, 2004 – Advitech (TSX-V: AVI), a Canadian biotech company currently involved in developing a new oral treatment for psoriasis, announced today several additions to its scientific team.
Dr. Patrice E. Poubelle, M.D., D.Sc. – Special Scientific Advisor and Chairman of the Scientific Advisory Board
Dr. Patrice E. Poubelle, M.D., D.Sc. becomes Special Scientific Advisor to the Company and will serve in that capacity as Advitech’s spokeperson on all scientific and medical issues. Dr. Poubelle will also chair Advitech’s Scientific Advisory Board and participate directly in certain aspects of the Company’s R&D program.
Dr. Poubelle has been a full-time professor at the Faculty of Medicine at Université Laval since 1995 and is a member of the Rheumatology and Immunology Research Unit at the Centre hospitalier de l'Université Laval (CHUL) Research Centre. He became Doctor of Medicine (M.D.) with a speciality in rheumatology in 1979 and obtained a D.E.A. in endocrinology at Montpellier (1979-1980, France). He was chief of clinic at the Rheumatology Service of Montpellier University Hospital Centre, France (1979-83).
Dr. Jean-Paul L. Marty, Ph.D., member of the Scientific Advisory Board
Dr. Jean-Paul L. Marty, Ph.D., joins Advitech’s Scientific Advisory Board. Dr. Marty is Professor of Dermopharmacology and Cosmetology at the Faculty of Pharmacy, Université de Paris-Sud. Since 1985, he has been a reviewer for the French Health Department’s Pharmaceutical Group for pharmaceutical product approval. He is the author or co-author of 230 papers and abstracts on pharmaceuticals, biopharmacy, cosmetology and dermopharmacology. He is also the recipient of numerous awards including the Prize of the French Society of Cosmetology (2000).
Ms. Christina Juneau, B.Sc. Director, Scientific Affairs
Ms. Juneau joins Advitech’s management team as Director, Scientific Affairs. Her responsibilities include supervising the upcoming XP-828L clinical study and other Company R&D programs. She oversees the continuing development of the company’s technology, the internal R&D team and cooperation with outside researchers.
Ms. Juneau has a B.Sc. in Biochemistry from Université Laval. She is currently completing her Ph.D. in Food Science also at Université Laval. She has over 11 years of experience in the biotech industry. She co-founded a leading Canadian biotech company at which she was involved in several scientific and regulatory aspects of product development, manufacturing and marketing. She is co-author of six patents and two patents pending related to the development, manufacturing and use of a bio-active compound destined for use for various medical conditions.
Dr. Yves Pouliot, until recently Vice-President, Research and Development. Dr. Pouliot, will return to his previous position of full-time Professor at Université Laval. He will remain involved with the company as Associate Researcher and will continue to play a key role in the development of the XP-828L platform. He joins Dr. Sylvie Gauthier of Université Laval who is also an Associate Researcher of Advitech. Both will participate in the long-term development of the company’s technologies.
“As we are about to begin our important multicentre, double-blind, placebo-controlled clinical study on XP-828L, our new oral treatment for psoriasis, we believed it was the appropriate time to bring in additional scientific expertise,” stated Renaud Beauchesne, President and CEO of Advitech. “I am more than pleased to welcome Dr. Poubelle, Dr. Marty and Ms. Juneau to our team. This is a significant contribution to the advancement of our company and I have no doubt that their combined knowledge will help us further our scientific program and bring new development as well.”
About Advitech Advitech specializes in the development of bioactive products derived from dairy proteins. Its key focus areas are in the fields of immunology and inflammatory processes. Its main platform, XP-828L, is a bioactive complex used in the development of an oral treatment for psoriasis and other immune system disorders. Advitech’s common shares are listed on the TSX Venture Exchange under the symbol AVI. The number of common shares outstanding is 54,799,818.
This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward- looking statements. The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release. For further information, please contact: Michel Lamontagne, MBA Vice President and Chief Financial Officer (418) 686-7498 ext. 237 [email protected] www.advitech.com